* Aronex Pharmaceuticals Inc., of The Woodlands, Texas, said preliminary results of 30-patient Phase I dose-escalating safety trial of Annamycin, an analogue of anthracycline, demonstrated the anti-cancer compound did not cause adverse side effects — such as cardiotoxicities, hair loss and skin irritations — associated with other anthracycline drugs. Two of four patients at the highest dose experienced low platelet counts. Annamycin is targeted for cancer patients who don't respond to available chemotherapy because of multi-drug resistance.